Saturday, October 18, 2025

Self-Invention

While artificial intelligence ("AI") deservedly dominates the headlines, another branch of technology is experiencing its own spectacular efflorescence:  biotechnology.  No one communicates the excitement and importance of the life sciences as elegantly and authoritatively as Dr. Matt Ridley, who, among many other accomplishments, received his doctorate in biology amidst the dreaming spires of the University of Oxford.  In a masterful article, provocatively entitled "Crispr gave humans the power to remake ourselves. What will we do with it? - On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the world", published on October 18, 2025, in Canada's newspaper of record, The Globe and Mail, he explores the momentous scientific and societal implications of genome editing.  I was delighted to be quoted twice in the article.  Everyone should read this article, for it challenges humanity to think carefully as we leap ever further into our own undiscovered biotechnological future.

Aukward Morality

 The always brilliant Matt Ridley published a wonderful article entitled "Welcome to the age of de-extinction" in The Spectator Magazine on October 4, 2025.  There, among other charismatic fauna, he discusses reviving and reintroducing into the wild one of my favorites:  the Great Auk.  I'm honored he mentioned my perspective on reviving extinct creatures whose extinctions we humans caused.  With work on the Dodo, Woolly Mammoth, Passenger Pigeon, and Tasmanian Wolf actively advancing, and three living analogues of the Dire Wolf - rather splendidly named Remus, Romulus, and Khaleesi - already prowling around their own secure compound, courtesy of Colossal Biosciences, humanity should be actively advancing policies for sound deextinction governance.

Saturday, September 20, 2025

Say "Cheese", But Not "Emmental"!

 I was delighted to be interviewed on TV about one of my favorite varieties of cheeses - Emmental - and Switzerland's quest to receive geographical indication protecction for this holely delicious, buttery, fruity, semi-firm cheese named for the Emme River Valley east of the city of Bern.

Wednesday, August 20, 2025

Innovation Hypercycles

Almost a year ago, on September 9, 2024, I was privileged to present my research on "Innovation Hypercycles - The Rise and Fall of Technological Hotspots" in my augural lecture as the Paul E. Wilson Distinguished Professor of Law at the University of Kansas.  The video is now available here.  My lecture was about 90 minutes long. I hope you enjoy my lecture.

Friday, August 1, 2025

The Economist Meets The Earth Biogenome Project!

 The Economist magazine focused favourably on the Earth Biogenome Project in its July 31st issue:

One ambitious proposal is the [EBP], a moonshot idea to sequence all the planet's eukaryotic life - that is, all plants, animals, fungi and so forth.  This would help scientists uncover the hidden handiwork of evolution, monitor how endangered species respond to global warming, and mine genomes for useful biological compounds, such as antibiotics.

I currently serve on the the EBP's Ethical, Legal, and Social Implications Committee, and I welcome this recognition of this immensely worthwhile Project.  The article is critical of the Nagoya Protocol on Access and Benefit-sharing of the Convention on Biological Diversity, suggesting that the Protocol impedes biodiversity research and the sharing of benefits from such research.  For that reason, The Economist suggests scrapping the Protocol.  However, like understanding a subject as complex as biodiversity, ditching the Protocol is far easier said than done! 

Tuesday, June 10, 2025

Front And Centaur

 My brilliant colleague, Bill Tomlinson, and I were delighted when the Texas A&M Journal of Property Law ("TAMUJPL") decided to publish four of our biodiversity law articles in a special issue.  The four articles can be found here:

Invasives: The How of Biodiversity Loss 
Population: The Who of Biodiversity Law 
Pollution: The What of Biodiversity Loss 
Overharvesting: The Why of Biodiversity Loss

The excellent editors penned a thoughtful introduction to the issue in which they announced a paradigm shift toward acceptance of articles produced by what Ethan Mollick has named the "Centaur" method.  Bill and I have been experimenting since 2022 on a project of integrating artificial intelligence ("AI") into the process of scholarly research and writing.  We even published an article in 2023 on how to write with AI, entitled "ChatGPT and Works Scholarly: Best Practices and Legal Pitfalls in Writing with AI".  This TAMUJPL special issue marks an important milestone in our project.

So, it was gratifying to see coverage of the special TAMUJPL issue, the special introductory editorial article, and our four articles in ABOVE THE LAW ("ATL") on June 9, 2025, and in the ABAJOURNAL on June 10, 2025.  The ATL article is entitled "Law Review Puts Out Full Issue Of Articles Written With AI, with a wonderful subtitle (that is, "Do androids dream of electric footnotes") that nods to one of Philip K. Dick's masterpieces.  The ABAJOURNAL article is entitled "AI takes on starring role in 4 articles published by law journal".

We hope Chiron, Cloudbirth, and Firenze would approve.

Tuesday, May 6, 2025

Quill To Query

 Thank you to Julianne Hill, who published "Does Artificial Intelligence Have a Role in Legal Scholarship?" in the ABAJOURNAL on May 2, 2025.  I was honored and delighted to be interviewed for the article.  The article also has a great photograph of my brilliant friend, Prof. Dan Linna of Northwestern Law School, along with his sage insights. 

Wednesday, April 2, 2025

The Right To Invent Tomorrow

 Aidan McCullen is an innovation leader.  Gifted entrepreneur, speaker, university lecturer, and former professional rugby player, he is the founder and host of The Innovation Show.  I was delighted to be Aidan's guest this past week.  We had a wonderful conversation together about roles the law plays, and could better play, in fostering innovation, especially in its open, user, collaborative, and free flavours.  Along the way, we discovered unexpected commonalities in ancestry and interests.  Here is my appearance on Aidan's The Innovation Show:

Thanks again, Aidan, for the golden opportunity to meet and speak with you about innovation and how to make it thrive.  I look forward to crossing paths with you again soon.

Maith thú, a dheartháir!

Saturday, January 25, 2025

Should California Stay Or Should It Go?

I had the good fortune of being interviewed by journalist Elizabeth Weise for her article, written with Josh Peter, today (January 24, 2025) in USA Today, entitled "A free California? Trump visits as initiative to leave U.S. cleared to gather signatures".  Her interest was sparked by an article Prof. Bill Tomlinson and I published in 2020, entitled "Fault Lines: An Empirical Legal Study of California Secession", available here.   Here's the article by Weise and Peter:  https://www.usatoday.com/story/news/nation/2025/01/24/country-of-california-secession-newsom-trump/77907859007/

The conundrum California faces is nicely summarized by The Clash, in its song, "Should I stay or should I go?":


Whatever route California decides to take, it will not easy:  "If I go, there will be trouble.  And, if I stay, it will be double."


Friday, December 8, 2023

After Casgevy Follows A Genome Editing Bevy

Today, December 8, 2023, the United States Food and Drug Administration ("FDA") emulated its British equivalent, the Medicines and Healthcare products Regulatory Agency, by approving the CRISPR/Cas9-based therapy Casgevy, a gene editing treatment for sickle cell disease ("SCD").  As it did in the United Kingdom, this approval marks a milestone in therapeutic history in the United States.   Here is how the FDA described Casgevy:

Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a type of genome editing technology. Patients’ hematopoietic (blood) stem cells are modified by genome editing using CRISPR/Cas9 technology.

CRISPR/Cas9 can be directed to cut DNA in targeted areas, enabling the ability to accurately edit (remove, add, or replace) DNA where it was cut. The modified blood stem cells are transplanted back into the patient where they engraft (attach and multiply) within the bone marrow and increase the production of fetal hemoglobin (HbF), a type of hemoglobin that facilitates oxygen delivery. In patients with sickle cell disease, increased levels of HbF prevent the sickling of red blood cells.

The FDA was impressed by the strong performance of Casgevy in clinical trials:

The safety and effectiveness of Casgevy were evaluated in an ongoing single-arm, multi-center trial in adult and adolescent patients with SCD. Patients had a history of at least two protocol-defined severe VOCs during each of the two years prior to screening. The primary efficacy outcome was freedom from severe VOC episodes for at least 12 consecutive months during the 24-month follow-up period. A total of 44 patients were treated with Casgevy. Of the 31 patients with sufficient follow-up time to be evaluable, 29 (93.5%) achieved this outcome. All treated patients achieved successful engraftment with no patients experiencing graft failure or graft rejection. 

The most common side effects were low levels of platelets and white blood cells, mouth sores, nausea, musculoskeletal pain, abdominal pain, vomiting, febrile neutropenia (fever and low white blood cell count), headache and itching.

The FDA granted the license for Casgevy to biotechnology firm, Vertex Pharmaceuticals Inc..  However, many other biotechnology and pharmaceutical companies are waiting in the line for the FDA to grant approval to their genome editing therapies. 

Thursday, November 16, 2023

Medicine's CRISPR Focus

 The United Kingdom Medicines and Healthcare products Regulatory Agency ("MHRA") made history today when it approved the medicine "Casgevy" for the treatment of sickle-cell disease and transfusion-dependent β-thalassemia in patients aged 12 and older.  As the MHRA announced in a press release,

Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020.  

Both sickle cell disease and β-thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body. Sickle cell disease is particularly common in people with an African or Caribbean family background. β-thalassemia mainly affects people of Mediterranean, south Asian, southeast Asian and Middle Eastern origin. 

In people with sickle cell disease, this genetic error can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia (whereby your body has difficulty carrying oxygen). 

In people with β-thalassaemia, it can lead to severe anaemia. Patients often need a blood transfusion every 3 to 5 weeks, and injections and medicines throughout their lives. 

Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin. To do this, stem cells are taken out of bone marrow, edited in a laboratory and then infused back into the patient after which the results have the potential to be life-long. 

Here's how Casgevy, developed by Vertex Pharmaceuticals in Boston, Massachusetts, and CRISPR Therapeutics in Zug, Switzerland, works:

Casgevy is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory. Patients must then undergo conditioning treatment to prepare the bone marrow before the modified cells are infused back into the patient. After that, patients may need to spend at least a month in a hospital facility while the treated cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.

Sickle-cell disease and transfusion-dependent β-thalassemia are painful and debilitating conditions that disproportionately afflict the poor.  Casgevy marks a landmark, heralding the beginning of CRISPR-based therapeutics approved for the market, and, more importantly, for the treatment of patients. 

Sunday, November 20, 2022

COPs And Robbers

 The 27th Conference of the Parties ("COP 27") to the Framework Convention on Climate Change ("FCCC") wrapped up several days late, on November 20, 2022, and myriad dollars short of those needed to limit global warning to 1.5°C.  Buried within its dense diplomatic verbiage, the "Draft decision" negotiated at COP 27 features two notable statements.  First, the goal of limiting global mean temperature rise to 1.5 °C remains squishy, with the parties not committing, but "resolv[ing] to pursue further efforts to limit the temperature increase to 1.5 °C" (Draft decision, I(7)).  Second, section VI of the Draft decision, entitled "Loss and damage", contemplates de facto liability by rich countries for damages caused to poorer countries by the effects of climate change.  To a betting person, the odds the world will exceed the "limit" of 1.5 °C would now seem to have shortened.  Meanwhile, the odds rich countries will come anywhere close to committing the financial resources necessary to meet the spirit of the new "loss and damage" obligation will surely start off as very long.

There is a silver lining to the Draft decision reached at COP 27:  once the 400 or so private jets that flew climate delegates and lobbyists to the negotiations depart, the carbon footprint of the host city, Sharm el-Sheikh, is likely to settle back down to its usual level.